107 growth-stage medtech investors
We list 107 growth-stage medtech investors as of November 2026: 70 have an SEC filing on file and 37 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (14), New York (9) and Massachusetts (8).
Top 5 growth-stage medtech investors, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Echo Health Ventures
Type: Corporate VC · HQ: Durham, NC · Stages: Growth · Focus: Medtech, Healthtech · Latest activity: Portfolio news, Sep 2026 · Private fund assets: $518M (SEC Form ADV)
Portfolio news dated Sep 2026; $518M on file (SEC Form ADV); 77% of its observed portfolio is medtech and medical devices; backs growth-stage; 2 named decision-makers on file.
JSTAR Capital
Type: VC firm · HQ: Austin, TX · Stages: Growth · Focus: Medtech, Healthtech, AI, Fintech · Latest activity: New fund, Aug 2026 · Fund size on file: $100M (SEC Form D, 2025)
Latest fund filing dated Aug 2026; $100M fund on file (SEC Form D, 2025); 62% of its observed portfolio is medtech and medical devices; backs growth-stage; 8 named decision-makers on file.
Mercia Asset Management
Type: Fund manager · HQ: Henley-in-Arden, United Kingdom · Stages: Seed, Series A, Growth · Focus: Medtech, Healthtech, Future of Work, AI · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: £400M (own site)
Portfolio news dated Oct 2026; £400M on file (own site); 100% of its observed portfolio is medtech and medical devices; backs seed, Series A, growth-stage; 8 named decision-makers on file.
Transformation Capital
Type: VC firm · HQ: Boston, MA · Stages: Growth · Focus: Medtech, Healthtech · Latest activity: New fund, Sep 2026 · Fund size on file: $800M (SEC Form D, 2022)
Latest fund filing dated Sep 2026; $800M fund on file (SEC Form D, 2022); states medtech and medical devices as a focus; backs growth-stage; 8 named decision-makers on file.
Whiterock
Type: Fund manager · HQ: Belfast, United Kingdom · Stages: Growth · Focus: Medtech, Media, Generalist, Climate Tech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: £255M (own site)
Portfolio news dated Oct 2026; £255M on file (own site); states medtech and medical devices as a focus; backs growth-stage; 8 named decision-makers on file.
First 25 of 107 growth-stage medtech investors
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Echo Health Ventures | Corporate VC | Durham, NC | Growth | Medtech, Healthtech | Portfolio news, Sep 2026 | $518M (SEC Form ADV) | 5 Nov 2026 | 2 names · Unlock |
| JSTAR Capital | VC firm | Austin, TX | Growth | Medtech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 4 Nov 2026 | 8 names · Unlock |
| Mercia Asset Management | Fund manager | Henley-in-Arden, United Kingdom | Seed, Series A, Growth | Medtech, Healthtech, Future of Work, AI | Portfolio news, Oct 2026 | £400M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Transformation Capital | VC firm | Boston, MA | Growth | Medtech, Healthtech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Whiterock | Fund manager | Belfast, United Kingdom | Growth | Medtech, Media, Generalist, Climate Tech | Portfolio news, Oct 2026 | £255M (own site) | 5 Nov 2026 | 8 names, firm email · Unlock |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Medtech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 4 Nov 2026 | 8 names · Unlock |
| NewVale Capital | VC firm | Boulder, CO | Growth | Medtech, Biotech, Healthtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Town Hall Ventures | VC firm | New York, NY | Growth | Medtech, Healthtech, Impact | New deal, Sep 2026 | $400M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Quartus | VC firm | New York, NY | Growth | Medtech, AI, Healthtech, B2B | New fund, Sep 2026 | $150M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Accelmed | VC firm | Aventura, FL | Growth | Medtech, Healthtech, Developer Tools, Biotech | Portfolio news, Apr 2026 | $401M (SEC Form D, 2021) | 5 Nov 2026 | 8 names, firm email · Unlock |
| HLM Investment Partners | VC firm | Waltham, MA | Growth | Medtech, Healthtech | New fund, Aug 2026 | $61M (SEC Form D, 2025) | 4 Nov 2026 | 4 names · Unlock |
| Claritas Signal Partners | VC firm | Nashville, TN | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Media | New deal, Aug 2026 | $14M (SEC Form D, 2021) | 5 Nov 2026 | 8 names · Unlock |
| Lauxera Capital Partners | VC firm | Paris, France | Growth | Medtech, Healthtech | New fund, May 2026 | €800M (own site) | 7 Nov 2026 | 4 names, firm email · Unlock |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Medtech, Healthtech, Biotech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 4 Nov 2026 | 4 names, firm email · Unlock |
| Parkwalk Advisors | SEIS/EIS fund | London, United Kingdom | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Industrial Tech | New fund, Sep 2026 | £500M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Sana Capital | VC firm | New York, NY | Growth | Medtech, Healthtech | New fund, Apr 2026 | $100M (SEC Form D, 2026) | 4 Nov 2026 | 5 names · Unlock |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Medtech, Healthtech, Biotech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Sprig Equity | VC firm | Wilmette, IL | Growth, Late stage | Medtech, Healthtech | New fund, Aug 2026 | $34M (SEC Form D, 2023) | 5 Nov 2026 | 6 names, firm email · Unlock |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Medtech, Healthtech, Biotech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 5 Nov 2026 | No contact on file |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Medtech, Healthtech, Biotech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Khosla Ventures | VC firm | Menlo Park, CA | Pre-seed, Seed, Series A, Growth | Medtech, AI, Consumer, B2B | New fund, Aug 2026 | $1.9B (SEC Form D, 2025) | 4 Nov 2026 | 8 names · Unlock |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Medtech, Biotech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| Eckuity Capital | VC firm | New York, NY | Growth | Medtech, Healthtech, Biotech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 4 Nov 2026 | 1 name · Unlock |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Medtech, Healthtech, AI, Robotics | New deal, Sep 2026 | 4 Nov 2026 | 3 names, firm email · Unlock | |
| Sandbox Clinical Ventures | VC firm | Chicago, IL | Seed, Series A, Series B, Growth | Medtech, Insurtech, Healthtech, AI | New fund, Sep 2026 | $100M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock |
You are seeing 25 of 107. The full list adds 82 more investors and 580 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 107 break down
By region
| Region | On this list | Share |
|---|---|---|
| United States | 69 | 64% |
| United Kingdom | 19 | 18% |
| Europe | 19 | 18% |
By US state
| US state | On this list | Share |
|---|---|---|
| California | 14 | 13% |
| New York | 9 | 8% |
| Massachusetts | 8 | 7% |
| Florida | 5 | 5% |
| Texas | 4 | 4% |
| Illinois | 3 | 3% |
| Connecticut | 3 | 3% |
| Tennessee | 2 | 2% |
| Georgia | 2 | 2% |
| Washington | 2 | 2% |
By European country
| European country | On this list | Share |
|---|---|---|
| France | 5 | 5% |
| Germany | 4 | 4% |
| Netherlands | 3 | 3% |
| Sweden | 2 | 2% |
| Luxembourg | 2 | 2% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 84 | 79% |
| Fund manager | 12 | 11% |
| Corporate VC | 4 | 4% |
| SEIS/EIS fund | 4 | 4% |
| Venture debt | 2 | 2% |
Method and limits
- Source
- 70 of the 107 rows carry an SEC filing (Form D or Form ADV). All 107 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states medtech and medical devices as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 7 Nov 2026.
- Fill rates
- Of 107 rows: stage 107, sector 107, fund size 82, website 107. In the paid file: named decision-makers on 98 rows, firm email on 51, LinkedIn page on 68, check size on 23.
- Corrections
- Email hello@theinvestordatabase.com or use the update form. We act within 5 working days.
Questions
How many growth-stage medtech investors are there?
We list 107 as of November 2026. 53 of the 107 have a fund filing or a dated deal in the last 12 months.
Which growth-stage medtech investors raised a new fund in the last 12 months?
22 of the 107 have a fund filing dated in the last 12 months. The most recent on this list are IVP: Venture capital for the Exceptional (Oct 2026), NewVale Capital (Oct 2026) and Transformation Capital (Sep 2026).
What is the typical fund size of growth-stage medtech investors?
The median fund size on file for this list is $150M, across the 46 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 61 do not disclose a size there.
How do I contact growth-stage medtech investors?
The paid file holds 580 named decision-makers across 98 of these 107 and a firm email for 51. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on growth-stage medtech investors come from?
70 of the 107 rows have an SEC filing on file (Form D or Form ADV) and 37 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Narrower lists
Related lists
Growth-stage SaaS investors (344)Growth-stage healthtech investors (316)Growth-stage AI investors (295)Seed medtech investors (278)Growth-stage fintech investors (214)Growth-stage deep tech investors (191)Growth-stage climate tech investors (189)Pre-seed medtech investors (129)Series A medtech investors (125)Growth-stage consumer investors (124)Growth-stage B2B investors (119)Growth-stage biotech investors (109)Growth-stage energy investors (102)Growth-stage cybersecurity investors (92)Growth-stage industrial tech investors (81)Growth-stage food and beverage investors (67)Series B medtech investors (57)Growth-stage mobility investors (55)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to medtech and medical devices and growth-stage. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.